This article aims to highlight the dosing issues of direct oral anticoagulants (DOACs) in patients with renal insufficiency and/or obesity in an attempt to develop solutions employing advanced data-driven techniques. DOACs have become widely accepted by clinicians worldwide because of their superior clinical profiles, more predictable pharmacokinetics, and hence more convenient dosing relative to other anticoagulants. However, the optimal dosing of DOACs in extreme weight patients and patients with renal impairment is difficult to achieve using conventional dosing approach. The standard dosing approach (fixed-dose) is based on limited data from clinical studies. The existing formulae (models) for determining the appropriate doses for these patient groups lead to suboptimal dosing. This problem of mis-dosing is worsened by the lack of standardised laboratory parameters for monitoring the exposure to DOACs in renal failure and extreme body weight patients. Model-informed precision dosing (MIPD) encompasses a range of techniques like machine learning and pharmacometrics modelling, which could uncover key variables and relationships as well as shed more light on the pharmacokinetics and pharmacodynamics of DOACs in patients with extreme body weight or renal impairment. Ultimately, this individualised approach-if implemented in clinical practicecould optimise the DOACs dosing for better safety and efficacy.
Introduction Despite the advantages of Direct Oral Anticoagulants (DOACs) over older classes of anticoagulants, clinical experience is limited in special populations; data from landmark trials on safety and efficacy are relatively scarce (compared to warfarin). This makes it challenging for clinicians to prescribe the right DOAC at the right dose for such patients (e.g., morbidly obese patients) (1). Insights derived from analysing real-world data have proven to be a vital source of clinical evidence backing the recommendation of medications (2). Therefore, data-driven technologies like machine learning can harness big data in electronic health records (EHRs) to optimise DOAC therapy and improve clinical outcomes. Aim The study aims to accurately predict clinical outcomes in morbidly obese patients, and identify the key variables in the model for optimising the safety and efficacy of Direct Oral Anticoagulant (DOAC) doses. Methods An observational, retrospective cohort study was carried out in partnership with an NHS Trust. Based on eligibility criteria, the dataset of morbidly obese patients on DOACs was extracted from EHRs, pre-processed and analysed considering the access granted. After partitioning the entire dataset into a 70:30 split, the training dataset (70%) was run through selected machine learning (ML) classifiers (Random Forest, decision trees, K-nearest neighbours (KNN), bootstrap aggregation algorithm, gradient boosting classifier, support vector machines, and logistic regression) to rank variables, and derive predictions which were evaluated against the test dataset (30%). A multivariate regression model was used to adjust for confounders and to explore the relationships between DOAC regimens and clinical outcomes. Results We identified 4,275 morbidly obese patients out of n=97,413 records overall. The bootstrap aggregation, decision trees, and random forest classifiers (from the ML algorithms tested) achieved superior prediction accuracies (98.6%, 97.9%, and 98.3%, respectively) for the individual DOAC doses, with excellent values for precision, recall, and F1 scores (performance metrics). The most important characteristics in the model for predicting mortality and stroke were age, treatment days, and length of stay. Among DOACs, apixaban (84%) was the most frequently prescribed DOAC followed by rivaroxaban (15%). Apixaban 2.5 mg (twice daily) received the highest ranking for relevance to mortality, while it raised the mortality risk (OR 1.430, 95% CI: 1.181, 1.1.732, p=0.001). There were mixed results for apixaban 5mg (twice daily), the most widely prescribed dose of apixaban (54%), with significantly reduced risk of mortality (OR 0.751, 95% CI: 0.632, 0.905, p=0.003), but significantly increased risk of stroke events (OR 32.457, 95% CI: 17.083-61.664, p=0.001). Conclusion Given the large sample size—a strength of our study, data-driven technologies were successfully employed in predicting the safety and efficacy of DOACs in morbidly obese patients using the real-world dataset; the key variables in the model for optimising clinical outcomes were identified. However, the limitations in our study, such as reporting errors, selection bias, and confounding bias, were not ruled out. Therefore, confirmatory studies (e.g., external validation with prospective data) are needed to confirm findings and provide a sound basis for universal deployment in clinical settings. References 1. Chen A, Stecker E, A. Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc. 2020 Jul 7;9(13):e017559. 2. Hu C, Liu Z, Jiang Y, Shi O, Zhang X, Xu K, et al. Early prediction of mortality risk among patients with severe COVID-19, using machine learning. Int J Epidemiol. 2021;49(6):1918–29.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.